Drug Profile
Darbepoetin alfa biosimilar - Biocad
Alternative Names: BCD 066; Darbepoetin α biosimilar - BiocadLatest Information Update: 07 Jun 2023
Price :
$50
*
At a glance
- Originator Biocad
- Class Antianaemics; Recombinant erythropoietins
- Mechanism of Action Erythropoiesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Anaemia
Most Recent Events
- 31 May 2023 Selexis has merged with KBI Biopharma to form KBI Biopharma
- 28 Oct 2020 No recent reports of development identified for phase-I development in Anaemia(In volunteers) in Russia (IV, Injection)
- 16 Jul 2020 Darbepoetin alfa biosimilar - Biocad is available for licensing as of 16 Jul 2020. https://biocadglobal.com/